Targeting of Tumor-Specific HLA Ligands with Bispecific T Cell-Engaging Receptor (TCER™) Molecules

Time: 9:00 am
day: Day One

Details:

  • XPRESIDENT® to exploit the repertoire of tumor-associated antigens
  • Introduction into TCER™, Immatics’ TCR bispecific molecules
  • TCER™ in vivo data

Speakers: